Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
Format: | Article |
---|---|
Language: | English |
Published: |
BMJ Publishing Group
2022-11-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/8/2/e002216corr1.full |
Similar Items
-
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
by: Astrid van Tubergen, et al.
Published: (2022-06-01) -
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
by: Mary K Crow, et al.
Published: (2023-03-01) -
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
by: Mary K Crow, et al.
Published: (2023-03-01) -
Correction: Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases
Published: (2023-10-01) -
Review of the European League Against Rheumatism (EULAR) guidelines considered in 2018
by: T. V. Beketova
Published: (2019-05-01)